Oelke Mathias

Chief Science OfficerNexImmune, Inc. (NEXI) · full profile →Form 4 · filed Apr 6, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
17
0 non-derivative · 17 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 4, 2023Grant(A)16K16K
Apr 4, 2023Disposed to issuer(D)16K0
Apr 4, 2023Grant(A)47K47K
Apr 4, 2023Disposed to issuer(D)47K0
Apr 4, 2023Grant(A)115K115K
Apr 4, 2023Disposed to issuer(D)115K0
Apr 4, 2023Grant(A)5K5K
Apr 4, 2023Grant(A)32K32K
Apr 4, 2023Disposed to issuer(D)5K0
Apr 4, 2023Disposed to issuer(D)32K0
Apr 4, 2023Grant(A)7K7K
Apr 4, 2023Grant(A)13K13K
Apr 4, 2023Disposed to issuer(D)20K0
Apr 4, 2023Grant(A)39K39K
Apr 4, 2023Grant(A)21K21K
Apr 4, 2023Disposed to issuer(D)60K0
Apr 4, 2023Grant(A)81K$081K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-023687) within minutes of acceptance. Every field above traces to the original document. Verify it directly: